AcquisitionsJun 2, 2026, 01:26 PM
OSR Holdings Acquires VXM01 IP from Subsidiary Vaximm for $30M
AI Summary
OSR Holdings, Inc. has entered into an Asset Purchase Agreement to acquire the VXM01 intellectual property family and related contracts from its indirect subsidiary, Vaximm AG. The purchase price is $30,000,000, payable upon the first milestone payment trigger under a related License Agreement, specifically the completion of a Phase 2 clinical study of VXM01. This transaction is intended to transfer direct ownership of the intellectual property to OSR Holdings, making it the direct beneficiary of future milestone and royalty payments and avoiding potential tax complications in Switzerland.
Key Highlights
- OSR Holdings, Inc. entered into an Asset Purchase Agreement with its indirect subsidiary, Vaximm AG.
- OSR Holdings will acquire all rights to the VXM01 intellectual property family and related contracts.
- The aggregate purchase price for the Purchased Assets is $30,000,000.
- The purchase price is due upon the first milestone payment trigger under the License Agreement.
- The first milestone is the completion of a Phase 2 clinical study of VXM01 in glioblastoma or pancreatic ductal adenocarcinoma.
- The transaction aims to transfer direct IP ownership to OSR Holdings to become the direct beneficiary of future milestone and royalty payments.
- The agreement is a related party transaction and is governed by Swiss law.
Price Impact
More from OSRH